Please ensure Javascript is enabled for purposes of website accessibility

Why Fluidigm Stock Is Soaring Again Today

By Keith Speights - May 12, 2020 at 11:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be banking on the company winning FDA emergency use authorization for its Biomark system in COVID-19 testing.

What happened

Shares of Fluidigm (FLDM 1.19%) were soaring 14.6% higher as of 10:55 a.m. EDT on Tuesday. The jump marked the second consecutive day of double-digit gains for the medical device stock. Fluidigm's momentum appears to be related to the expanding opportunities for use of the company's systems in COVID-19 testing.

So what

Fluidigm announced its first-quarter results on Thursday, May 7, 2020. The immediate reaction to the company's Q1 update wasn't great. Fluidigm's revenue fell 8% year over year, and the company reported a wider adjusted net loss than it had in the prior-year period.

COVID-19 printed against blue background with red plastic balls representing the coronavirus

Image source: Getty Images.

However, investors appear to have shrugged off those less-than-stellar results and are instead focusing on Fluidigm's growth prospects. The company's Biomark system allows labs to process up to 6,000 samples each day and is already being used for COVID-19 testing. Fluidigm's mass cytometry platform is also being used to measure immune response in experimental COVID-19 treatments.

The company is working toward obtaining an emergency use authorization (EUA) from the FDA this quarter for its Biomark system in COVID-19 testing. Currently Fluidigm's customers are filing for EUAs for their COVID-19 testing using Biomark. If Fluidigm wins its own EUA for the Biomark system, it should help the company land more business.

Now what

The COVID-19 pandemic caused some challenges for Fluidigm, as customers significantly slowed down their testing in the wake of the viral outbreak. However, those issues should be temporary. Assuming that the FDA grants an EUA to the Biomark system for use in COVID-19 testing, Fluidigm could emerge from the crisis stronger than before. The healthcare stock's momentum seems to indicate that investors are counting on this to happen.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fluidigm Corporation Stock Quote
Fluidigm Corporation
FLDM
$1.70 (1.19%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.